The MYO18B antibody targets the MYO18B protein, a member of the unconventional myosin XVIII family involved in cellular processes such as cytoskeletal organization, intracellular trafficking, and cell motility. Unlike conventional myosins, MYO18B lacks a functional ATPase domain but contains unique N-terminal domains, including a pleckstrin homology (PH) domain, suggesting roles in signal transduction or membrane interactions. MYO18B is implicated in cancer biology, with studies linking its dysregulation to tumor progression, metastasis, and poor prognosis in cancers like hepatocellular carcinoma, lung cancer, and ovarian cancer. It may act as a tumor suppressor by modulating integrin signaling or interacting with growth factor receptors (e.g., PDGFRβ) to influence cell adhesion and migration. MYO18B antibodies are essential tools for detecting protein expression and localization via techniques like Western blotting, immunohistochemistry, or immunofluorescence, aiding research into its mechanistic roles and diagnostic potential. Recent studies also explore its association with inherited disorders, including skeletal muscle defects and immune dysfunction, highlighting its broader physiological relevance. However, the exact molecular pathways remain incompletely understood, necessitating further investigation using MYO18B-specific antibodies to clarify its functions in health and disease.